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disease development and response to immunotherapy, and 
extend fundamental knowledge related to T cell recognition 
patterns and cross-recognition by TCRs. MHC multimer-
based technologies have now evolved from detection of 
1–2 different T cell specificities per cell sample, to include 
more than 1000 evaluable pMHC molecules using novel 
technologies. Here, we provide an overview of MHC mul-
timer-based detection technologies developed over two dec-
ades, focusing primarily on MHC class I interactions.
Keyword MHC multimer · T cell receptor · MHC class 
I · Antigen specificity · DNA barcode-labeled MHC 
multimers
Abbreviations
AG+  Antigen positive
CLIP  Class II-associated invariant chain peptide
CyTOF  Cytometry by time-of-flight
NACS  Nucleic acid cell sorting
p*  UV-cleavable peptides
pMHC  Peptide-MHC
SA  Streptavidin
Introduction
Techniques for the detection of antigen-responsive T cells 
exploit the interaction between a given TCR and its pMHC 
recognition motif. T cell detection using multimerized 
pMHC molecules has evolved into the preferred method for 
detecting antigen-specific T cells. Over the past 20 years, 
since the first multimerizations of pMHC molecules [1], 
several approaches have aimed at matching the heteroge-
neity of T cells and epitope presentation to enhance our 
ability to map immune responses. The evolution of these 
Abstract T cell-mediated recognition of peptide-major 
histocompatibility complex (pMHC) class I and II mol-
ecules is crucial for the control of intracellular pathogens 
and cancer, as well as for stimulation and maintenance of 
efficient cytotoxic responses. Such interactions may also 
play a role in the development of autoimmune diseases. 
Novel insights into this mechanism are crucial to under-
standing disease development and establishing new treat-
ment strategies. MHC multimers have been used for detec-
tion of antigen-responsive T cells since the first report by 
Altman et  al. showed that tetramerization of pMHC class 
I molecules provided sufficient stability to T cell receptor 
(TCR)-pMHC interactions, allowing detection of MHC 
multimer-binding T cells using flow cytometry. Since 
this breakthrough the scientific community has aimed for 
expanding the capacity of MHC multimer-based detection 
technologies to facilitate large-scale epitope discovery and 
immune monitoring in limited biological material. Screen-
ing of T cell specificity using large libraries of pMHC mol-
ecules is suitable for analyses of T cell recognition poten-
tially at genome-wide levels rather than analyses restricted 
to a selection of model antigens. Such strategies provide 
novel insights into the immune specificities involved in 
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approaches, in terms of increasing complexity, is shown in 
Fig. 1.
MHC multimer technologies have primarily been devel-
oped and applied for analyses of CD8 T cell responses, 
because MHC class I molecules have proven easier to han-
dle in terms of protein folding and expression. Additionally, 
the MHC class I binding groove is more restricted in terms 
of the length of peptide bound—hence, it is more straight-
forward to predict MHC class I binding peptides. Most of 
the technologies described in this review relate to detection 
of specific CD8 T cell responses, but they are in principle 
also applicable to MHC class II multimers and detection 
of CD4 T cell responses. Specific challenges associated 
with the production and use of MHC class II multimers are 
addressed in the final section.
MHC molecules are largely unstable when they are not 
part of a complex with peptide. For this reason, pMHC-
based technologies were initially restricted by the tedi-
ous production of pMHC molecules, where each peptide 
required an individual folding and purification procedure 
[2, 3]. Thus, the development of high-throughput strate-
gies for T cell identification was constrained by the lim-
iting step involving the generation of large libraries of 
pMHCs. A number of potential solutions to this challenge 
have been developed in the last decade. First, Schumacher 
et  al. described the use of conditional MHC ligands that 
are cleaved upon exposure to 366 nm UV-light and can be 
exchanged with any MHC ligand of interest [4]. Using this 
strategy, individual MHC class I molecules are correctly 
refolded with carefully designed UV-cleavable peptides 
(p*), allowing sufficient stability of the complex. Indi-
vidual p*MHC molecules are purified, and stored to serve 
as a source of stock molecules that can be exchanged with 
any ligand of interest upon exposure to UV-light. The UV-
cleavable conditional ligand-strategy has enabled the pro-
duction of large numbers of different pMHC molecules in 
a high throughput manner [5, 6]. Today, such UV-ligands 
have been designed for a number of different MHC class 
I alleles, of both human and murine origin [7, 8]. An 
alternative strategy is the preferential folding of correctly 
oxidized MHC class I heavy chains. This allows efficient 
folding-reactions in small volumes, reduces the need for 
further optimization and can be used to create large librar-
ies of diverse pMHC complexes [9]. More recently, it was 
discovered that certain di-peptides can assist folding and 
peptide exchange of MHC class I molecules [10, 11]. Di-
peptides bind specifically to the F pocket of MHC class I 
molecules to facilitate peptide exchange and have so far 
Fig. 1  Evolution of MHC-based detection of antigen-responsive 
T cells. The methodologies are shown on a Log scale with increas-
ing complexity in terms of the reported number of distinct antigen-
responsive T cell populations that may by identified per sample. Most 
of the strategies offer the potential to screen for T cell reactivity at 
higher complexities. The listed sensitivities are based on screening 
for antigen-specific recognition among 2 × 106 viable cells, though the 
mass cytometry and matrix-based approaches require a higher num-
ber of input cells. The DNA barcode-based methodology has been 
reported to have an increased sensitivity with an increased number of 
input cells. AG+ antigen positive, CyTOF cytometry by time-of-flight
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been described and validated for peptide exchange in HLA-
A*02:01, HLA-B*27:05, and H-2Kb molecules. The di-
peptide exchange technology has not yet been applied in 
larger T cell epitopes mapping strategies. Together, these 
technologies have enabled efficient production of large 
libraries of pMHC molecules, and consequently high-
throughput detection of CD8 T cell recognition using 
pMHC-based reagents.
Strategies for high-throughput detection 
of antigen-responsive T cells
All the MHC-based strategies described throughout this 
report are summarized in Table 1.
Detecting antigen-responsive T cells using MHC 
microarrays
Early attempts to improve the complexity of MHC mul-
timer-based detection of antigen-responsive T cells were 
based on the success of gene-expression arrays, including 
the availability of efficient systems capable of quantify-
ing fluorescent probes when spatially separated as spots 
on a microarray [12]. Protein-based microarrays have been 
developed [13] and the idea of a pMHC microarray allow-
ing cell-capture based on specificity is appealing. Although 
several such systems have been developed [14–19], their 
application seems to be limited on account of a poor detec-
tion limit and low reproducibility compared to existing 
cytometry-based analyses. There is considerable overlap 
between MHC microarray approaches, where most work 
has focused on optimizing the supporting surface and 
modifying the conditions applied during binding and/or 
washing.
In early studies by Soen et  al. [14] and Chen et  al. 
[16], microscope slides coated with polyacrylamide were 
selected as the optimal surface to lower cellular interac-
tion while aiding protein binding. In these studies, the 
researchers were able to screen for seven different antigen-
specificities in parallel and detect populations of T cells at 
a minimum frequency of 0.1% of total CD8 T cells [14] or, 
sensitivity may be enhanced up to tenfold when isolating 
CD8 T cells prior to loading them onto the microarray [16]. 
Using similar approaches, Stone et  al. [15] and Brooks 
et  al. [19] showed a considerable increase in complexity, 
screening for 30–40 different antigen-responsive T cells in 
parallel, while also achieving a detection limit of approxi-
mately 0.1% of CD8 T cells. Using microarray approaches 
pMHC molecules can be co-spotted either with cytokine 
capture antibodies [16] or co-stimulatory molecules [15]. 
This may provide additional functional information to the 
T cell identification process. Moreover, the visualization of 
activation markers once the T cells are captured at pMHC 
specific spots may improve the sensitivity of the assay [15, 
16]. The study by Chen relied solely on T cell activation 
from multimeric pMHC:TCR interaction; however, multi-
meric pMHC:TCR interaction cannot be expected to acti-
vate all relevant T cells. Thus, counting on a lower detec-
tion limit due to the capture and visualization of activation 
markers would also increase the risk of missing those T cell 
populations that were not activated in such a system or mis-
interpreting their frequency.
A general limitation with such array-based strategies 
is the propensity of a given T cell to pursue all potential 
pMHC interactions displayed on a given array. As a conse-
quence, the frequency of antigen-responsive T cells in the 
cell preparations should be >0.1% to allow a robust read-
out. Deviren et al. [17] particularly addressed the issue of 
assay reproducibility and homogeneity, and by introducing 
a mild flow shear they obtained a more uniform distribution 
of captured T cells and a higher reproducibility. Consist-
ent with the issue of ensuring cell interaction at all possi-
ble pMHC positions, they noted a greater variability asso-
ciated with decreased surface area of each spotted pMHC. 
The nucleic acid cell sorting (NACS) approach developed 
by Kwong et  al. [18] employed unique sequences of sin-
gle-stranded DNA conjugated to distinct pMHC tetramers, 
which in turn were site-specifically assembled via hybridi-
zation onto glass slides printed with complementary DNA 
probes. This strategy offers an advantage over other MHC 
arrays in that T cells can be recovered from the glass slide 
by selective detachment using restriction enzymes.
Detecting antigen-responsive T cells using 
combinatorially labeled MHC multimers
An alternative approach to pMHC microarrays is to uti-
lize the increasing number of fluorescent labels available 
for flow cytometry. Two such parallel approaches were 
described in 2009, using combinatorial encoding of fluores-
cently labeled MHC multimers. Both of these approaches 
take advantage of the assumption that any given T cell in 
the cell samples will only bind one of the pMHC molecules 
in a given library. Thus, each distinct pMHC multimer can 
be assigned with a unique dual color code [20] or multi-
valent code [21], which is then used to identify the T cells 
binding to this particular pMHC molecule. When employ-
ing the unique dual color code, any T cell not matching 
the pre-determined color combinations is recorded as a 
background event. This provides a low limit of detec-
tion (0.002%) and a clear distinction between background 
events and specific pMHC binding with T cells. However, 
both approaches require that peptide sequences with mini-
mal variation are analyzed in separate samples, to avoid 
cross-recognition between peptides within a given sample.
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With the emergence of mass cytometry that uses heavy 
metal ions as tags, there has been a dramatic leap in the 
number of labels that can be applied in parallel [22–24]. 
Combining mass cytometry with combinatorial pMHC 
tetramer staining using a total of 10 metal labels applied 
in unique combinations of three labels per MHC mul-
timer, Newell et al. were able to screen for 109 different 
antigen-specificities in one sample, while still leaving a 
substantial number of labels for parallel phenotype and 
functional analysis of T cells [25]. Despite the obvious 
progress made using this assay, there are a number of 
drawbacks associated with mass cytometry which may 
have impeded the widespread use of the method. This 
includes low cell recovery in the instrument (~30%), 
slow collection speed (~300 events/s), relatively low 
resolution, and high instrument and reagent cost [26]. 
Most importantly, the instrument offers no way of recov-
ering distinct populations, as the cell structure is fully 
disrupted during the process. Thus, potential combina-
tion with genomic or transcriptomic sequencing-based 
approaches is not feasible.
More recently, a matrix-based approach has been devel-
oped for T cell identification. In this method, a set of MHC 
multimers are split into matrix-defined pools, in such a way 
that no specific MHC multimer are present in all pools. 
The multimer pools are used to stain an equal number of 
cell aliquots derived from a given sample. The approach 
uniquely combines antigen recognition with sequenc-
ing of the TCRβ chain in that the MHC multimer positive 
and negative populations of each reagent pool are sorted 
and clonotypes enriched within the positive population 
are identified [27]. The advantage of this approach is that, 
theoretically, the number of antigen-responsive T cells that 
can be assessed in parallel increases exponentially with the 
number of pools created. In practice, 16 antigen-specifici-
ties have been analyzed in parallel (8 pools with 4 differ-
ent MHC multimers per pool). The same study also uses 
an alternative, non-MHC-based approach that applies stim-
ulation with different pools of peptides and sorting of the 
activated subset of T cells to screen for recognition of 30 
peptide-antigens in parallel.
This forms an attractive tool for detecting many anti-
gen-responsive T cells simultaneously, especially since it 
also enables the identification of the corresponding TCRβ 
clonotypes. However, the necessity to split samples into a 
number of pools represents an inherent drawback in terms 
of detecting rare T cell populations especially in patient 
material that is often of limited access.
Thus, until recently no technology has been available 
that simultaneously permits high-throughput analyses of 
T cells while tolerating the large diversity of T cell anti-
gen specificity, thereby allowing detection of epitopes at 
potentially genome wide levels even in limited biological 
samples, and recovery the positively interacting T cells for 
gene expression analysis.
Next generation detection of antigen-responsive T 
cells using DNA barcode-labeled MHC multimers
The most recent addition to the immunologist toolbox for 
detecting T cells based on antigen recognition involves 
implementation of a new type of label. Instead of using 
fluorescence or metal labels, as described in previous sec-
tions, we [28] have applied unique DNA barcodes that 
when attached to MHC multimers, form specific tags for 
the given pMHC epitopes. DNA barcodes can be designed 
with a complexity of up to  1010 different sequences, each 
forming a unique tag [29]. As a result, this strategy is not 
limited by the number of available labels, which has pre-
viously been the most critical barrier to high-throughput 
detection of antigen-responsive T cells. We have shown 
that this approach can be applied to screen for more than 
1000 specificities in a single sample. These MHC multim-
ers are generated on a backbone of polysaccharide dextran 
that carries a number of free streptavidin (SA) binding 
sites. These SA binding-sites are used to co-attach bioti-
nylated molecules, recombinant pMHCs, and DNA bar-
codes (Fig. 2). In this manner, every pMHC epitope is asso-
ciated with a unique DNA barcode (e.g., barcode#1 codes 
for pMHC#1, barcode#2 codes for pMHC#2 and so on) 
that can be easily recovered by high-throughput sequenc-
ing. Moreover, all MHC multimers are conjugated to the 
same fluorochrome (PE), whose signal-intensity serves as 
a means to collectively sort any T cells that associate with 
the MHC multimers. Thus, first the T cells are incubated 
with large collections (>1000) of DNA barcode-labeled 
MHC multimers and all multimer positive cells are sorted, 
and then the associated DNA barcodes are amplified and 
the unique sequences revealed after sequencing (Fig.  2). 
Ultimately, the number of reads for a specific DNA bar-
code matching the corresponding pMHC correlates with 
the presence of antigen-responsive T cells within the sorted 
population.
In contrast to both single MHC multimer staining and 
combinatorial encoding of MHC multimers (using either 
fluorescence or metal labels) where the signal intensities 
are applied directly to define the antigen recognition of a 
given T cell population, the antigen-responsiveness deter-
mined using DNA barcode-labeled MHC multimers are 
defined in a retrospective analysis of sequence reads, pro-
viding an estimate for the number of antigen-responsive T 
cells rather than the exact number. Unique molecular iden-
tifiers [30] are incorporated in the DNA barcode design to 
provide a means of accounting for amplification bias, and 
thus the number of sequence reads reflects the number of 
662 Cancer Immunol Immunother (2017) 66:657–666
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specific pMHC:TCR interactions in the population as a 
whole. In other words, when calculating the frequency of 
antigen-responsive T cells based on the number of barcode 
reads and the frequency of total multimer-positive cells, the 
determined frequencies are based on an average number of 
pMHC:TCR interactions for all T cells in the potentially 
heterogeneous population. This strategy may introduce a 
bias in frequency determination, depending on pMHC:TCR 
affinity and TCR expression level on the given cell popula-
tion. Practically, this phenomenon seems to provide limited 
variability to the DNA barcode-based determination of T 
cell frequencies, resulting in a very tight correlation with 
T cell frequencies determined by combinatorially encoded 
fluorescently labeled MHC multimers [r2 = 0.967, across 
10 healthy donors (32 responses) and r2 = 0.901 across 11 
melanoma patients (15 responses)] [28].
The DNA barcode-based approach offers the advan-
tage that it is less dependent on stringent fluorescent-based 
separation of multimer-positive from multimer-negative 
events, because even events that may not be fluorescently 
separated due to low level pMHC multimer interactions 
will still bind enough DNA barcode-labeled MHC mul-
timers to allow recovery of their specific DNA barcode 
element, thus enabling the identification of the TCR speci-
ficity. The technology therefore represents an attractive 
tool for detecting low avidity TCR:pMHC interactions 
such as shared tumor-associated antigens. When applying 
cytometry-based approaches, the signal intensity associ-
ated with a given pMHC is the only measure distinguish-
ing those T cells that interact specifically with MHC mul-
timers and those that do not. Therefore, it is essential that 
a given T cell binds numerous MHC multimers, to obtain 
sufficient fluorescence intensity and thereby enable unam-
biguous identification of their specificity. A T cell that has 
low affinity TCR:pMHC interactions or low surface TCR 
expression may not bind sufficient MHC multimers to 
obtain fluorescent separation, but will still provide a signal 
from the attached DNA barcode. We have demonstrated 
that the antigen-responsive composition of T cells in a sam-
ple can be determined independent of any fluorescent label, 
by sorting the whole CD8 T cell population as opposed to 
only the multimer-positive T cells [28].
In line with the reasoning that antigen recognition 
can be determined from the number of DNA barcode 
reads irrespective of the fluorescent-based separation of 
multimer-positive cells, other criteria can be applied to 
determine which cell populations to sort. Throughout the 
workflow of the DNA barcode-based strategy only a few 
different fluorescent labels are applied to determine the via-
ble CD8 positive population, leaving a considerable num-
ber of fluorescent labels to stain for other cell properties. 
Thus, one can distinguish between CD8 T cells with certain 
phenotypic characteristics or of a certain activation status, 
and retrospectively determine the composition of antigen-
responsive T cells among the different populations through 
sequencing of the associated DNA barcodes. This strategy 
was illustrated with the activation of antigen-responsive T 
cells present in healthy donor blood or tumor-infiltrating 
lymphocytes (TILs), through stimulation with a pool of 
common virus-derived peptides or autologous tumor cell 
line, respectively. Subsequently, samples are stained with 
collections of DNA barcode-labeled MHC multimers and 
intracellular activation markers. The fluorescent signal 
from the MHC multimers was disregarded and cells were 
sorted exclusively based on the cytokine secretion profile 
[28]. Thus, we have shown that DNA barcodes associated 
Fig. 2  Detection of antigen-responsive T cells using the DNA bar-
code-labeled MHC multimer methodology. A PE-labeled dextran 
backbone carrying a number of SA binding sites (illustrated as an 
X) is applied to co-attach biotinylated molecules; DNA barcodes and 
pMHCs. Thus >1000 pMHC multimers can be generated, each car-
rying a different DNA barcode. All MHC multimer binding T cells 
are sorted based on the common fluorescent label and the associated 
DNA barcodes are amplified and sequenced. The relative numbers of 
DNA barcode reads are used to determine the composition of anti-
gen-responsive T cells in the sample
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with pMHC multimers recognized by T cells that have 
been exposed to their target antigen, can completely or pre-
dominantly be recovered from the activated subset of CD8 
T cells. On the other hand, the DNA barcodes associated 
with epitopes not available for T cells during stimulation 
are only found in the non-activated subset of CD8 T cells. 
TCR downregulation following T cell activation has previ-
ously conflicted with effective combinations of MHC mul-
timer staining and T cell activation for low-avidity T cells; 
however, the DNA barcode-labeled strategy seems to be 
less sensitive to such phenomena, because even low levels 
of pMHC multimer interactions (insufficient for fluorescent 
separation) will retain a DNA barcode signal, as described 
above [28].
Inarguably, the greatest advantage of using DNA bar-
code-labeled MHC multimers is the possibility to screen in 
an unbiased manner for T cell reactivity across large librar-
ies of pMHC epitopes in a single sample. Applying the cur-
rent DNA barcode design, we can generate unique labels 
in the order of  1010; thus the technology has the potential 
for analyzing T cell reactivity at close to genome-wide lev-
els. Using earlier high-throughput methodologies it has not 
been possible to analyze for T cell reactivity of structurally 
related pMHC epitopes in the same sample, e.g., peptides 
differing only at a single amino-acid position or 9-, 10- or 
11-mer versions of the same peptide with a given HLA 
restriction. However, this issue could be circumvented 
without much difficulty since these strategies, being only 
semi-high-throughput, have often required the splitting of 
samples into several tubes to analyze all potential epitopes 
of interest. Users simply have to ensure that different ver-
sions of a pMHC epitope were represented in different 
MHC reagent mixtures. However, with the possibility of 
screening, e.g., a full cancer-mutagenome in one sample, it 
is essential that structurally related pMHC epitopes can be 
identified in parallel using only one mixture of MHC rea-
gents. The DNA barcode-based approach provides informa-
tion on recognition of a given pMHC molecule, but such 
recognition may likely be shared among several T cell 
populations. Thus, cross reactivity to multiple epitopes in a 
given library will not disrupt analyses. Analyzing the cross-
reactive features and relative recognition profile among dif-
ferent pMHC complexes can be accomplished when T cells 
are assessed at a single cell level.
The DNA barcode labeling of MHC multimers provides 
a new tool to gain insight to T cell recognition in complex 
disease situations. Nonetheless, the main disadvantage of 
the methodology is that it merely provides an estimate for 
T cell frequencies, and does not offer any possibility for 
direct visual assessment of the findings in terms of T cell 
recognition. Thus, users rely on good quality assurance of 
the sequencing procedure and validated programs to trans-
late read number into the presence of antigen-responsive 
T cells. Furthermore, pMHC binding T cells are lysed in 
the process of DNA barcode amplification, and are conse-
quently not available for subsequent cell culturing.
Novel insights into T cell recognition of cancer
Due to the limited number of cells available directly from 
excised tumor fragments, it has for most prior purposes 
been necessary to expand TILs in  vitro to enable analy-
ses of antigen recognition of the relevant pMHC multimer 
molecules. Previous studies have shown that expansion of 
T cells may introduce a bias in antigen recognition due to 
variable growth potential of TILs, and specifically, pref-
erential growth of T cell populations that recognize virus 
epitopes [31]. Application of large-scale screening strate-
gies reduces the need for such in vitro expansion of T cells, 
and allows for T cell recognition analyses on broad spectra 
of pMHC epitopes even in minute amounts of patient mate-
rial. We have shown the possibility for detection of anti-
gen-responsive T cells towards a large shared melanoma 
library (composed of 175 DNA-barcoded MHC multimers) 
in tumor digest from melanoma patients without the need 
for T cell expansion [25]. Moreover, because of the amount 
of data that can be recovered from a relatively small sized 
sample, the DNA barcode-based methodology represents 
an attractive tool to analyze patient samples taken at mul-
tiple time-points, to follow the dynamics of an immune 
response and the response to certain treatments.
Since it is no longer necessary to split samples into mul-
tiple aliquots to screen for antigen recognition, it is possi-
ble to look for T cell recognition in an unbiased fashion in 
samples with a considerably greater number of precursor 
cells than what had previously been applied. With increas-
ing cell numbers, the stochastic variation of the composi-
tions of antigen-specific T cell populations is reduced, and 
the chance for detecting low-frequent T cell populations 
increases, reflecting a higher absolute number of pMHC 
responsive T cells in the given sample.
The advantages of being able to include more T cells in 
the initial binding reaction were illustrated in a study where 
we screened for T cell recognition of predicted HLA-bind-
ing peptide sequences containing cancer-specific muta-
tions in two patients with non-small cell lung carcinoma. 
A large number of personal neoepitope peptides had been 
predicted for each patient resulting in libraries of 288 and 
417 different pMHCs, respectively [32]. In these patients, 
T cell recognition was assessed from analyzing in  vitro 
expanded TILs from one or more regions of lung tissue. 
A total of one neoepitope-responsive T cell population 
was detected using combinatorial encoding of fluorescent 
labels, which allowed the inclusion of only 1 × 106 TILs/
MHC reaction mixture (9–13 different reaction mixtures/
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patient specific neoepitope library). Despite the limited 
availability of sample, we were able to detect a total of nine 
different neoepitope-responsive T cells when applying the 
DNA barcode-based MHC multimer technology. This may 
partly be explained by the greater number of cells included 
in the initial binding reactions (4–8 × 106 TILs in one MHC 
reaction mixture) and due to the possibility for analyzing 
peripheral blood. In fact, several of the detected responses 
were predominantly or exclusively found in the peripheral 
blood sample [28].
MHC class II multimers for detection 
of antigen-responsive CD4 T cells
An additional challenge in the field of immune analyses 
relates to the characterization of antigen-responsive CD4 T 
cells. Antigen-responsive CD4 T cells are believed to play 
a significant role in tumor-cell recognition [33, 34] and 
development of autoimmune diseases [35, 36]. Detection 
of antigen-specific CD4 T cells using MHC II multimers 
is feasible [37], but high-throughput detection strategies 
are still challenging. MHC class II molecules require, for 
most alleles, expression in mammalian cells [38], although 
more recent strategies has proven that functional HLA-
DR molecules can be expressed and refolded from E. coli 
[39]. Peptide exchange can be facilitated using constructs 
that includes a thrombin cleavage site next to a class II-
associated invariant chain peptide (CLIP). MHC II are pro-
duced with CLIP embedded in the peptide binding groove, 
but following thrombin-based cleavage of the linker, CLIP 
can be displaced by simple competition with ligands of 
interest. This strategy has been exploited to generate small 
libraries of MHC II molecules, DRB1*0101, DRB1*0401, 
DRB5*0101 and DRB1*1501 [40]. Importantly, it is much 
more difficult to predict which peptides will form stable 
complexes with MHC class II compared to class I since 
the open structure of the MHC II molecule enables peptide 
fragments to protrude from the binding groove and thus 
allows much more variable side chains of cargo peptides 
[41]. Moreover, it is presumed that CD4 TCRs bind with 
lower affinity to their cognate pMHC epitope than CD8 
TCRs [42]. This may be a particularly important limita-
tion in the ability to detect self-antigen and tumor-specific 
 CD4+ T cell populations.
Along with the improvements in prediction tools for 
MHC-II ligands [43] and the development of efficient pep-
tide replacement systems for generating large libraries of 
MHC class II monomers [40], the technologies for large-
scale detection of antigen-responsive CD8 T cells described 
herein should also be feasible for detection of CD4 T cells. 
Specifically, the DNA barcode-based methodology may 
provide an advantage, compared to the other methods, for 
detection of CD4 T cells using MHC II multimers, due to 
its particular advantages in terms of detecting T cells with 
low-affinity TCR:pMHC interactions, that are not well sep-
arated based on fluorescence labeling alone. However, the 
use of DNA barcode labeled MHC II multimers has not yet 
been investigated.
Future implications
At present proof-of-principle have been provided that up 
to 1031 DNA barcode-labeled MHC multimers can be 
applied in one reaction mixture to detect several popula-
tions of antigen-responsive T cells in parallel. This com-
plexity, though already representing a tenfold leap com-
pared to earlier methodologies, can potentially be increased 
to >10,000–100,000 differently labeled MHC multimers. 
Since the potential complexity of the DNA barcode label 
is in the order of  1010, the limitations inherent to combi-
natorial encoding using fluorescent or metal tags have 
been removed. However, new bottlenecks may arise with 
increasing library sizes. Moving the complexity of MHC 
multimer libraries within the range of 10,000–100,000 
specificities will require automation of all aspects of the 
pMHC multimer production as well as more efficient and 
cost-effective production of synthetic peptides. Further-
more, it will most likely require the development of micro-
fluidics systems that can ensure efficient pMHC interaction 
with all T cells in a given sample.
In the era of personalized medicine and with accumulat-
ing types of immunotherapeutic strategies being employed, 
it is becoming increasingly important to understand the 
T cell-mediated recognition of cancer cells, and identify 
biomarkers predicting the response to therapy—poten-
tially based on experimental analyses of T cell recognition 
(Fig. 3).
Recent data suggest that a substantial fraction of the 
T cell reactivity induced during checkpoint inhibition is 
directed towards neoepitopes that are generated through 
genetic alterations [44–46]. However, current tools for 
neoepitope prediction are imprecise and identification of 
tumor-rejection epitopes at genome-wide levels requires 
large-scale analyses of T cell reactivity. The recently devel-
oped technology based on DNA barcode-labeled MHC 
multimers has the potential to improve such T cell analy-
ses, and importantly, enables detection of T cells in both 
peripheral blood and tissue biopsies [28]. Furthermore, 
increasing knowledge of the T cell recognition profile in 
cancer patients can be used to improve prediction tools for 
cancer-specific neoepitopes, and help in identifying the 
impact of genetic heterogeneity in T cell recognition [32].
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